Literature DB >> 26587960

Symptoms of thyrotoxicosis, bone metabolism and occult atrial fibrillation in older women with mild endogenous subclinical hyperthyroidism.

Pedro Weslley Rosario1, Marina Carvalho1, Maria Regina Calsolari1.   

Abstract

OBJECTIVE: The objective of this study was to evaluate symptoms of thyrotoxicosis, bone turnover, bone mineral density (BMD) and occult atrial fibrillation (AF) in women ≥65 years with mild endogenous subclinical hyperthyroidism (SCH).
DESIGN: Cross-sectional and case-control study. PATIENTS: Signs and symptoms of thyrotoxicosis, serum carboxyterminal telopeptide (CTx) and procollagen type I N-terminal propeptide (PINP), BMD, resting electrocardiogram (ECG) and 72-h ECG monitoring were evaluated in 180 women ≥65 years, including 90 with mild SCH (TSH between 0·1 and 0·4 mIU/l) and 90 euthyroid controls matched for age and body mass index.
RESULTS: Symptom Rating Scale scores did not differ between patients and controls. None of the patients with SCH scored 20 points, a score compatible with clinical thyrotoxicosis. Eighty patients with SCH (89%) obtained seven or fewer points, a score compatible with euthyroidism. No difference in serum CTx or PINP concentrations was observed between patients and controls. There was also no correlation between these markers and TSH, free T4 or total T3 levels. Finally, no difference in femoral neck or lumbar spine BMD was observed between patients with SCH and controls. Three patients with SCH (3·3%) and two euthyroid women (2·2%) had known AF or AF in the resting ECG. ECG monitoring for 72 h revealed episodes of occult AF in 1/87 patients with SCH and in 1/88 euthyroid women (1·1%).
CONCLUSIONS: Mild endogenous SCH (TSH between 0·1 and 0·4 mIU/l) was not associated with symptoms of thyrotoxicosis, altered bone metabolism or a higher prevalence of occult AF in women ≥65 years.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26587960     DOI: 10.1111/cen.12979

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Thyrotoxicosis in patients with hypothyroidism is not just overtreatment.

Authors:  Punith Kempegowda; Ananth U Nayak
Journal:  BMJ Case Rep       Date:  2017-07-14

2.  Risk of Osteoporotic Fractures after Thyroid-stimulating Hormone Suppression Therapy in Patients with Thyroid Cancer.

Authors:  Youjin Lee; Byung-Ho Yoon; Seeyoun Lee; Youn Kyung Chung; Young-Kyun Lee
Journal:  J Bone Metab       Date:  2019-02-28

3.  Influence of Thyroid-stimulating Hormone Suppression Therapy on Bone Mineral Density in Patients with Differentiated Thyroid Cancer: A Meta-analysis.

Authors:  Byung-Ho Yoon; Youjin Lee; Hyun Jin Oh; Sung Han Kim; Young-Kyun Lee
Journal:  J Bone Metab       Date:  2019-02-28

Review 4.  Effect of Thyroxine and Thyrotropin on Bone Mineral Density in Postmenopausal Women: A Systematic Review.

Authors:  Prakar Poudel; Roopa Chalasani; Mastiyage R Goonathilake; Sara Waqar; Sheeba George; Wilford Jean-Baptiste; Amina Yusuf Ali; Bithaiah Inyang; Feeba Sam Koshy; Kitty George; Lubna Mohammed
Journal:  Cureus       Date:  2022-06-26

Review 5.  Thyroid Hormone Diseases and Osteoporosis.

Authors:  Alessandro P Delitala; Angelo Scuteri; Carlo Doria
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.